Open Access

Introduction.

Topic: Treatment
Sponsored by PACE-CME – Supported by an unrestricted educational grant from Amarin Pharma

Congress Presentation

About the speaker

Professor Ulrich Laufs

University hospital Leipzig AoR, Leipzig (Germany)
30 presentations
1 follower

4 more presentations in this session

Assessing residual cardiovascular risk in patients already treated with statin therapy.

Speaker: Professor A. Zambon (Padua, IT)

Thumbnail

Exploring the role of icosapent ethyl based on current clinical evidence.

Speaker: Professor J. Jukema (Leiden, NL)

Thumbnail

Icosapent ethyl: what are the most likely mechanisms of benefit?

Speaker: Professor C. Packard (Glasgow, GB)

Thumbnail

Discussion.

Thumbnail

Access the full session

Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl

Speakers: Professor U. Laufs, Professor A. Zambon, Professor J. Jukema, Professor C. Packard
Thumbnail

About the event

Image

ESC Preventive Cardiology 2022

7 April - 9 April 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk